Last updated: February 20, 2026
What is the Therapeutic Profile of NDC 64980-0331?
NDC 64980-0331 refers to Avastin (bevacizumab), a monoclonal antibody used to inhibit vascular endothelial growth factor (VEGF). It is approved primarily for multiple cancers, including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, and certain eye diseases like age-related macular degeneration.
Current Market Size and Demand
Global cancer therapeutics market was valued at approximately $175 billion in 2022, expected to grow at a compound annual growth rate (CAGR) of 8% from 2023 to 2030 [1]. Bevacizumab remains a significant driver, comprising roughly 12-15% of this segment.
Market Breakdown
| Region |
Market Share (2022) |
CAGR (2023-2030) |
Notes |
| North America |
45% |
7% |
Largest market, dominated by U.S. healthcare system |
| Europe |
25% |
8% |
Rising demand in EU for oncology agents |
| Asia Pacific |
20% |
11% |
Fastest growth, expanding access |
| Other Regions |
10% |
6% |
Emerging markets, increasing coverage |
Key Drivers
- Increasing cancer incidence globally, especially colorectal and lung cancers.
- Adoption of combination therapies utilizing bevacizumab.
- Expansion of approved indications, notably in ophthalmology for retinal diseases.
Competitive Landscape
Primary competitors include:
- Roche's Avastin (original-labeled bevacizumab)
- Zirabev (biosimilar to Avastin, Amgen)
- Mvasi (biosimilar by Pfizer)
- Beovu (Novartis), although targeting retinal diseases more specifically.
Biosimilars entered the U.S. market in 2019-2020, leading to price competition and market share shifts.
| Product |
Launch Year |
Price in US (per dose) |
Market Share (2022) |
| Avastin |
2004 |
$3,200 - $3,600 |
~70% |
| Zirabev |
2019 |
$1,800 - $2,200 |
~15% |
| Mvasi |
2019 |
$1,700 - $2,000 |
~10% |
Pricing Dynamics and Projections
Current Price Trends
- Original Avastin pricing stabilizes around $3,200 to $3,600 per dose.
- Biosimilar entry has decreased average prices by approximately 40-50%.
Short-term Price Projections (2023-2025)
- Biosimilars will comprise over 30% of the market, pressuring prices.
- A gradual decrease in Avastin's price is expected, reaching $2,800–$3,000 per dose by 2025.
- Biosimilars' prices are expected to plateau around $1,600–$2,000 per dose.
Long-term Outlook (2026-2030)
- Patent expirations and biosimilar uptake will likely reduce Avastin’s per-dose price by roughly 20-30% from 2025 levels.
- Market growth driven by expanding indications and geographic expansion is expected to offset price declines somewhat.
- Price range forecast: $2,200–$2,800 per dose.
Regulatory and Policy Influences
- Patent landscape: Avastin’s primary patent expired in 2017 in the U.S., facilitating biosimilar competition.
- Pricing regulations: Tightening drug pricing policies in the U.S. and some European countries could further pressure prices.
- Reimbursement policies: Increased adoption of biosimilars in Medicare and private payers via formulary inclusion will influence pricing dynamics.
Revenue Projections
Assuming annual sales volume remains stable or slightly increases due to expanded indications:
| Year |
Estimated Market Volume (units) |
Revenue (USD Millions) |
Comments |
| 2023 |
2.4 million |
$6.8 billion |
Biosimilar availability enhances volume, prices slightly decrease |
| 2025 |
2.6 million |
$7.2 billion |
Market growth offsets price drop |
| 2030 |
3.2 million |
$7.0 - $8.0 billion |
Increased indications, biosimilar competition stabilizes revenue |
Key Takeaways
- Avastin faces significant biosimilar competition, driving prices downward.
- The global market remains robust due to high demand across oncology and ophthalmology.
- Prices are projected to decline gradually through 2030, but total revenue remains stable due to market expansion.
- Bioslay constraint pressures will continue, especially in the U.S. and EU markets.
- Major revenue will accrue from emerging markets with expanding healthcare access.
FAQs
-
What are the primary drivers for Avastin's market growth?
Increasing cancer incidence, especially colorectal and lung cancers, and expanding approved indications support growth.
-
How will biosimilars affect Avastin's pricing in the next five years?
Biosimilars will decrease the average per-dose price of Avastin by approximately 20-30% by 2030.
-
What regional differences influence Avastin’s market size?
North America owns the largest share, followed by Europe and Asia Pacific, where rapid healthcare infrastructure expansion drives demand.
-
Are new indications likely to significantly impact Avastin sales?
Yes, including its approval for certain eye diseases and potential expansion in other oncology treatments.
-
What factors could alter the current price projections?
Policy changes, patent litigation, new biosimilar entrants, and development of next-generation therapies.
References
[1] Grand View Research. (2022). Cancer Therapeutics Market Size, Share & Trends Analysis Report.
